Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This review discusses the enigmatic nature of frontal fibrosing alopecia and reports no clinical results; the authors stress the need for further research.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study reports that familial frontal fibrosing alopecia was diagnosed earlier in premenopausal women compared to postmenopausal women, though long-term outcomes remain uncertain without a definitive treatment.

This study reports that high-frequency ultrasound can characterize frontal fibrosing alopecia by assessing dermal atrophy, hair follicle changes, and subclinical inflammation.

This study explored the secretion and cellular localization of different forms of follistatin and FST-like-3, revealing variable secretion kinetics and possible intracellular roles, particularly for nuclear FSTL3.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

This review discusses the increasing reports of frontal fibrosing alopecia, a form of scarring alopecia, and its potential link to autoimmune disorders, but reports no new clinical results.

This article discusses the DOAJ, a comprehensive index of international open access journals, and emphasizes its role in providing free quality content online without presenting new research findings.

In this case report, researchers identified a potential adverse skin reaction, called SDRIFE or Baboon syndrome, caused by the drug tofacitinib in a 19-year-old woman being treated for alopecia subtotalis, leading the authors to recommend discontinuation of the drug.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

In this study, researchers found that the health state utility of moderate facial angiofibroma in Tuberous Sclerosis Complex patients is significantly lower compared to almost-clear facial angiofibroma, indicating that treatment for the condition can substantially improve quality of life.

This article appears to be a table of contents or navigation page for a journal, not presenting any new findings or research results.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This article presents a case study of a 50-year-old woman with frontal fibrosing alopecia and discusses the role of dermoscopy in differentiating it from other types of alopecia, reporting no new clinical results.

This study explored the effects of TTFE on male androgenic alopecia, finding that topical application increased hair density, follicular diameter, and scalp hydration while reducing water loss and sebum production in a 12-week trial.

This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.

This correspondence discusses proposed updates to the diagnostic criteria for frontal fibrosing alopecia, emphasizing the importance of differentiating it from other types of alopecia.

This review discusses the possible immune-mediated and environmental factors contributing to frontal fibrosing alopecia but reports no new clinical findings, emphasizing the need for standardized treatment evaluations.

This study found that individuals with frontal fibrosing alopecia have increased odds of thyroid disease, lupus erythematous, vitiligo, and heart disease, supporting the consideration of FFA as a systemic disorder.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

This review provides a detailed analysis of frontal fibrosing alopecia, focusing on its prevalence in postmenopausal Caucasian women, associated comorbidities, and potential autoimmune, genetic, hormonal, and environmental factors; it emphasizes the need for improved understanding to enhance diagnosis and treatment.